Assenagon Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Assenagon Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$111M	Sell	454,682 -411,276	-47%	-$89.2M	0.14%	122
2026 Q1	$146M	Buy	865,958 +397,976	+85%	+$68.7M	0.22%	77
2025 Q4	$85.5M	Buy	467,982 +173,211	+59%	+$24.2M	0.12%	141
2025 Q3	$35.8M	Buy	294,771 +113,811	+63%	+$12.8M	0.05%	274
2025 Q2	$18.9M	Sell	180,960 -446,458	-71%	-$47.3M	0.03%	362
2025 Q1	$73.2M	Buy	627,418 +623,717	+16,853%	+$71.1M	0.12%	147
2024 Q4	$313K	Sell	3,701 -782	-17%	-$71.9K	﹤0.01%	1241
2024 Q3	$403K	Sell	4,483 -29,486	-87%	-$2.57M	﹤0.01%	1270
2024 Q2	$2.73M	Buy	+33,969	New	+$2.52M	0.01%	807

Other funds holding AXSM

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

TAM

Tealwood Asset Management Minneapolis, Minnesota $261M AUM 52.68% 1-Year Est. Return

Cannon Advisors Charlotte, North Carolina $164M AUM 30.34% 1-Year Est. Return

MCP

Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return

HCM

Howland Capital Management Boston, Massachusetts $2.77B AUM 19.56% 1-Year Est. Return

Assenagon Asset Management's AXSM Position: Q2 2026 in Review

Assenagon Asset Management reduced its Axsome Therapeutics (AXSM) stake by 47% in Q2 2026, selling an estimated $89.2M and leaving 454,682 shares worth $111M. The position accounts for 0.14% of the portfolio, ranked #122.

Assenagon Asset Management first reported a position in AXSM in Q2 2024 and has held it in 9 quarters since. The position peaked at $146M in Q1 2026. 38 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Assenagon Asset Management held 454,682 shares of Axsome Therapeutics worth $111M as of Q2 2026.
Assenagon Asset Management sold 411,276 Axsome Therapeutics shares in Q2 2026, an estimated $89.2M.
Axsome Therapeutics made up 0.14% of Assenagon Asset Management's portfolio in Q2 2026, its #122 holding.
Assenagon Asset Management first reported a position in Axsome Therapeutics in Q2 2024 and has held it in 9 quarters since.
Assenagon Asset Management's Axsome Therapeutics position peaked at $146M in Q1 2026.
38 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.